StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Dulera by Quarter

Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

Merck Dulera: $65M in Q4 2018, down 15.6% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2018
65
Period ended Dec 31, 2018
Change on a year earlier
-15.6%
77 in Q4 2017
History
8 quarters
Since Q1 2017
Sources
4
Documents cited below

Where the Q4 2018 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2019-02-27) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDulera (mometasone/formoterol, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2018Dec 31, 201865-15.6%Form 10-K (filed 2019-02-27) ↗
Q3 2018Sep 30, 201850-15.3%Form 10-Q (filed 2018-11-06) ↗
Q2 2018Jun 30, 201842-39.1%Form 10-Q (filed 2018-08-07) ↗
Q1 2018Mar 31, 201857-30.5%Form 10-Q (filed 2018-05-08) ↗
Q4 2017Dec 31, 201777–Form 10-K (filed 2019-02-27) ↗
Q3 2017Sep 30, 201759–Form 10-Q (filed 2018-11-06) ↗
Q2 2017Jun 30, 201769–Form 10-Q (filed 2018-08-07) ↗
Q1 2017Mar 31, 201782–Form 10-Q (filed 2018-05-08) ↗

Breakdown

What makes up dulera

Cite this data

StockData. (2026). Merck Dulera ($M), quarterly Q1 2017–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dulera

See every metric in the Merck KPI table. Data updated Oct 26, 2026.